HCW starts Precigen at buy; PT $5

H.C. Wainwright initiated coverage of Precigen (NASDAQ:PGEN) with a “buy” rating and $5 price target. The stock closed at $3.17 on May 7.

Precigen, previously known as Intrexon, is focused on applying synthetic biology technologies across diverse end markets, including healthcare, food, energy, and environment. In January 2020, Intrexon executed a restructuring plan to focus on the healthcare industry and solidified its capital position by divesting a number of non-healthcare assets for approximately $65-million and changed its name to Precigen.

The new Precigen’s healthcare business primarily comprises Intrexon’s wholly-owned subsidiaries, including PGEN Therapeutics; Precigen ActoBio; and Exemplar Genetics, as well as the majority stake in Triple-Gene, writes analyst Swayampakula Ramakanth.

Precigen is developing platforms for next-generation gene and cell therapies for the treatment of oncologic and autoimmune disorders. Its three core therapeutic platforms, UltraCAR-T, AdenoVerse, and ActoBiotics, have been used to develop treatments for a broad range of indications, he added.

Mr. Ramakanth said Precigen is developing a total of 20 product candidates both independently and through partnerships, with four of these programs as the most important value drivers.

They included PRGN-3005, an UltraCAR-T candidate for the treatment of platinum-resistant advanced ovarian cancer; PRGN-3006, an UltraCAR-T candidate for the treatment of relapsed or refractory acute myeloid leukemia and higher-risk myelodysplastic syndrome; PRGN-2009, an AdenoVerse candidate for the treatment of human papillomavirus associated solid tumors; and AG019, a first-in-class disease-modifying therapy built on ActoBiotics platform for the prevention, delay, or reversal of Type 1 diabetes.

“In our view, Precigen’s diversified development strategy helps to mitigate the clinical risk associated with any single program,” Mr. Ramakanth said.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.